Correlation Between Inozyme Pharma and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Molecular Partners AG, you can compare the effects of market volatilities on Inozyme Pharma and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Molecular Partners.

Diversification Opportunities for Inozyme Pharma and Molecular Partners

-0.38

Correlation Coefficient

Inozyme Pharma  Molecular Partners

Very good diversification

The 3 months correlation between Inozyme and Molecular is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Molecular Partners go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Molecular Partners

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Molecular Partners. In addition to that, Inozyme Pharma is 1.11 times more volatile than Molecular Partners AG. It trades about -0.01 of its total potential returns per unit of risk. Molecular Partners AG is currently generating about 0.04 per unit of volatility. If you would invest  533.00  in Molecular Partners AG on September 16, 2024 and sell it today you would earn a total of  10.00  from holding Molecular Partners AG or generate 1.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Molecular Partners AG

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inozyme Pharma and Molecular Partners

The main advantage of trading using opposite Inozyme Pharma and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Inozyme Pharma and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.